SI-BONE to participate in 24th Annual Needham Virtual Growth Conference
SI-BONE, a leader in surgical treatments for musculoskeletal disorders, announced participation in the 24th Annual Needham Virtual Growth Conference on January 12, 2022, at 5:00 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
SI-BONE, a leader in surgical treatments for musculoskeletal disorders, announced participation in the 24th Annual Needham Virtual Growth Conference on January 12, 2022, at 5:00 p.m. ET. The conference highlights the company’s innovative iFuse Implant System, which addresses SI joint pain affecting 15%-30% of chronic low back pain patients. With over 60,000 procedures performed by more than 2,500 surgeons, the iFuse system is supported by significant clinical evidence and insurance coverage. For more information, visit www.si-bone.com.
Details
News Market Reaction – SIBN
The recorded move for SIBN in the trading session of this news was -2.99%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SANTA CLARA, Calif., Dec. 27, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced management is scheduled to participate in the following investor conference:
24th Annual Needham Virtual Growth Conference on Wednesday, January 12, 2022 at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time.
Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company’s website at: www.si-bone.com.
About SI-BONE, Inc.
SI-BONE (NASDAQ: SIBN) is a global leader in technology for surgical treatment of musculoskeletal disorders of the sacropelvic anatomy. In 2009, SI-BONE introduced the iFuse Implant System for minimally invasive surgery of the SI joint, shown to be a source of pain in
For additional information about the company or products, including risks and benefits, please visit www.si-bone.com.
SI-BONE and iFuse Implant System are registered trademarks of SI-BONE, Inc. ©2021 SI-BONE, Inc. All Rights Reserved.
Investor Contact:
Matt Bacso, CFA
investors@si-bone.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.